2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). With increasing approval of CAR T-cell products and advances in CAR T cell therapy, CAR T cells are expected to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ping, Liu, Yang, Liang, Yun, Bo, Jian, Gao, Sujun, Hu, Yongxian, Hu, Yu, Huang, He, Huang, Xiaojun, Jing, Hongmei, Ke, Xiaoyan, Li, Jianyong, Li, Yuhua, Liu, Qifa, Lu, Peihua, Mei, Heng, Niu, Ting, Song, Yongping, Song, Yuqin, Su, Liping, Tu, Sanfang, Wang, Jianxiang, Wu, Depei, Wang, Zhao, Xu, Kailin, Ying, Zhitao, Yang, Qingming, Zhang, Yajing, Shi, Fengxia, Zhang, Bin, Zhang, Huilai, Zhang, Xi, Zhao, Mingfeng, Zhao, Weili, Zhao, Xiangyu, Huang, Liang, Zhu, Jun, Qian, Wenbin, Han, Weidong, Liang, Aibin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2023
Materias:
Consensus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978889/
https://www.ncbi.nlm.nih.gov/pubmed/36861439
http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978889/
https://www.ncbi.nlm.nih.gov/pubmed/36861439
http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0585

Ejemplares similares